Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Poseida Therapeutics

Poseida Therapeutics

Poseida Therapeutics develops targeted cell therapy founded in 2014 by Eric Ostertag.

All edits by  Sameeha Sulaiman 

Edits on 15 Feb, 2019
Sameeha Sulaiman
Sameeha Sulaiman edited on 15 Feb, 2019
Edits made to:
Article (+996/-6 characters)
Table (+1 rows) (+3 cells) (+184 characters)
Article

Poseida's leading product candidate is P-BCMA-101, an autologous CAR-T product that targets B cell maturation antigen, or BCMA, which is expressed on multiple myeloma cells. In December 2018, the compaycompany announced positive results from its first cohort of ongoing Phase 1 clinical trial. Poseida's second autologous product is P-PSMA-101, targeting cells that express prostate-specific membrane antigen, which is expressed on most prostate cancer cells. The product is being developed to treat patients with castrate-resistance prostate cancer, or CRPC, a solid tumor indication, with Phase 1 clinical trials planned in the second half of 2019.

Under the allogenic category, Poseida has P-BCMA-ALL01 and P-MUC1C-101. Derived from healthy donors, P-BCMA-ALL01 is designed to have the same inherent properties and functions of P-BCMA-101, but with the benefits of scale and administration efficiency that come from an allogenic product. The company plans to file an IND and begin Phase 1 clinical trials by late 2019 or early 2020. As for P-MUC1C-101, the product is in late-stage pre-clinical development for multiple solid tumor indications with plans for Phase 1 clinical trials in 2020.

In January 2019, Poseida Therapeutics filed documents for an IPO of $115 million.

Table

Title
Author
Link
Type

Xconomy: Poseida Therapeutics Prepares for IPO to Advance CAR-T Treatments

Web

Sameeha Sulaiman
Sameeha Sulaiman edited on 15 Feb, 2019
Edits made to:
Infobox (+3/-1 properties)
Article (+704/-227 characters)
Table (+11 rows) (+22 cells) (+467 characters)
Table (+1 rows) (+4 cells) (+396 characters)
Article

Poseida's CAR T cell therapy is genetically engineered immune cells that hone in on a cellular target present on the cancer cells, but not on any essential cells.

Poseida Therapeutics is a privately held, biopharmaceutical company based in San Diego California. It leverages proprietary non-viral, gene engineering technologies to create therapeutics for illnesses with high unmet medical needs. The company is developing a wholly-owned pipeline of autologous and allogenic CAR-T product candidates, initially focused on the treatment of hematological malignancies and other solid tumors.

...

On April 3, 2018, Poseida announced $30.5m in series B funding.

Poseida's leading product candidate is P-BCMA-101, an autologous CAR-T product that targets B cell maturation antigen, or BCMA, which is expressed on multiple myeloma cells. In December 2018, the compay announced positive from its first cohort of ongoing Phase 1 clinical trial.

Table

Name
Role
Related Golden topics

Debra Gessner

VP, Regulatory Affairs

Devon J. Shedlock

VP, Preclinical Development

Glenn Dourado

VP, Business Development

Jeff Knight

VP, Clinical Development Operations and Project Management

Jennifer Collins

VP, Quality Operations

Table

Title
Author
Link
Type

Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting

Poseida Therapeutics, Inc.

Web

Infobox
Golden logo
By using this site, you agree to our Terms & Conditions.